{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
First approved in 2009
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2019)
Source URL:
First approved in 2009
Source:
21 CFR 347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
HASOL Intensive Scalp Tonic by ECOMINE Co., Ltd.
(2014)
Source URL:
First approved in 2009
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03780595: Phase 4 Interventional Unknown status Benzodiazepine Withdrawal (Disorder)
(2018)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
JNH Magic BB by Daeduck Lab Co., Ltd
(2012)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2009
Source:
Prefera OB plus DHA by Alaven Pharmaceutical LLC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125347
(2009)
Source URL:
First approved in 2009
Source:
BLA125347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ORANGE BOOK:PANCRELIPASE (LIPASE) [ORANGE BOOK]
Source URL:
First approved in 2009
Source:
BLA020725
Source URL:
Class:
STRUCTURALLY DIVERSE